
Photocure ASA
OSE:PHO

Photocure ASA
PP&E Net
Photocure ASA
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Photocure ASA
OSE:PHO
|
PP&E Net
kr36.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
32%
|
CAGR 10-Years
28%
|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
PP&E Net
kr229.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
N
|
Navamedic ASA
OSE:NAVA
|
PP&E Net
kr8.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
35%
|
CAGR 10-Years
67%
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
PP&E Net
kr10k
|
CAGR 3-Years
-86%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.

See Also
What is Photocure ASA's PP&E Net?
PP&E Net
36.2m
NOK
Based on the financial report for Dec 31, 2024, Photocure ASA's PP&E Net amounts to 36.2m NOK.
What is Photocure ASA's PP&E Net growth rate?
PP&E Net CAGR 10Y
28%
Over the last year, the PP&E Net growth was 8%. The average annual PP&E Net growth rates for Photocure ASA have been 3% over the past three years , 32% over the past five years , and 28% over the past ten years .